Monday, December 23

Tag: Genomics

Startups Are Using AI to Predict Responses to Cancer Drugs
28Dec By adminNo Comments
World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Illumina to Divest Itself of Cancer-Test Maker Grail
18Dec By adminNo Comments
World

Illumina to Divest Itself of Cancer-Test Maker Grail

Gene-sequencing company Illumina said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle against U.S. antitrust regulators.Illumina said it will pursue the divestiture through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of next year.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive 
16Dec By adminNo Comments
World

Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive 

A federal appeals court said the U.S. government was right to challenge Illumina’s purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission for reconsideration.A three-judge panel found the deal to be anticompetitive, but said the FTC erred in how it considered Illumina’s proposed fix for its drawbacks. The judges ordered the FTC to reconsider its opinion on the troubled deal, which the European Commission has already ordered Illumina to unwind.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
23andMe Hack Is a Wake-Up Call for Your Password Habits
6Dec By adminNo Comments
Technology

23andMe Hack Is a Wake-Up Call for Your Password Habits

The recent breach of 23andMe user accounts shows a simple yet powerful truth about data security: Don’t reuse passwords, people.The DNA test-kit company on Monday reported a hacker accessed 14,000 accounts because of password reuse, exposing information belonging to approximately 6.9 million people. The 23andMe computer network wasn’t breached and wasn’t the source of these compromised credentials, a company spokesman said in a statement. The company first disclosed the incident in October and has been investigating since then.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Gene Editing Will Change Medicine—and Maybe Health Investing Too
24Nov By adminNo Comments
Money

Gene Editing Will Change Medicine—and Maybe Health Investing Too

It usually takes time for scientific discoveries in the lab to make their way to the market.The groundbreaking gene-editing technology known as Crispr, which acts like a molecular pair of scissors that can be used to cut and modify a DNA sequence, has moved rather quickly from the pages of scientific journals to the medical setting. Earlier this month, about three years after Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for describing how bacteria’s immune system could be used as a tool to edit genes, regulators in the U.K. approved the first Crispr-based treatment for sickle cell disease and beta-thalassemia patients. The treatment, from Vertex Pharmaceuticals and Crispr Therapeutics, could be approved by the U.S. Food and Drug Administration early next mo...
Read More